London · Delayed Price · Currency is GBP · Price in GBX Scancell Holdings Company Description
Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom.
Its product candidates include SCIB1/iSCIB1+ that is in Phase II for the treatment of melanoma; and SC134, an antibody for the treatment of small cell lung cancer.
It also develops Modi-1, an active peptide immunotherapy that is in phase II clinical trials for the treatment of solid tumors, including renal, head and neck, ovarian and triple negative breast cancers; and Modi-2, which targets stress-induced post translational modifications, such as homocittrullination.
In addition, the company provides GlyMab platform that generates various affinity tumour specific monoclonal antibodies (mAb) targeting glycans that are over-expressed on cancer cells; and AvidiMab, which romotes receptor clustering thereby improving immune signalling.
Scancell Holdings plc was founded in 1996 and is based in Oxford, the United Kingdom.
| Country | United Kingdom |
| Founded | 1996 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 60 |
| CEO | Phillip L’Huillier |
Contact Details
Address: Bellhouse Building Oxford, OX4 4GD United Kingdom | |
| Phone | 44 18 6558 2066 |
| Website | scancell.co.uk |
Stock Details
| Ticker Symbol | SCLP |
| Exchange | London Stock Exchange AIM |
| Fiscal Year | May - April |
| Reporting Currency | GBP |
| ISIN Number | GB00B63D3314 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Phillip L’Huillier | Chief Executive Officer |
| Sathijeevan Nirmalananthan | Chief Financial Officer |